THE LIBRARY: WHITEPAPER
Mitigating Phase 2 Development Risks
Phase 2 is the end of the road for many molecules and for others the source of later delays and denials. Learn techniques for mitigating the risks that threaten your development program in the new white paper, Mitigating Phase 2 Development Risks: Design and Operational Strategies and Case Studies for Phase 2 Success. Download the white paper today!
Latest Commentary
Combating HIV: The future of therapeutic vaccines
10 promising therapeutic vaccines in 2012
The 20 top-selling vaccines in H1 2012
GeoVax: Meeting the HIV vaccine challenge
Wishing you a happy HIV Vaccine Awareness Day
more
EVENTS
- CAPA Webinar Part 3: Effectiveness Checking and Management ReviewDownload Today
- FierceBiotech Executive Breakfast: Fast Phase IIIs October 21, 2014 — Boston, MA — Sponsored by Covance and INC Research
- Drug Development Boot Camp - November 19-20, 2014, Boston, MANovember 19-20, 2014 — Boston, MA — Hosted by Harvard University OTD and Speid & Associates, Inc.
Press Releases
- Nexstim Plans an Initial Public Offering on NASDAQ OMX First North
- Threshold Pharmaceuticals Announces Its Phase 3 Trial of TH-302 in Patients With Advanced Soft Tissue Sarcoma Will Continue as Planned Following Protocol-Specified Interim Analysis
- Threshold Pharmaceuticals Announces Its Phase 3 Trial of TH-302 in Patients With Advanced Soft Tissue Sarcoma Will Continue as Planned Following Protocol-Specified Interim Analysis
- Cytori Consolidates and Restructures Its Operations, Provides Business Update
- Ebola treatment trials to be fast-tracked in West Africa
- More Press Releases
Featured Jobs
> Need a job? Need to hire? Visit our jobs site.